Behavioral Health

Obsessive-compulsive disorder: diagnosis and treatment

Clinical Overview and When to Suspect OCD

— Lifetime prevalence ~2–3% in US adults; equal sex distribution in adulthood, male predominance in childhood-onset.

— Bimodal onset: early peak at ages 8–12, late adolescence/early adulthood (mean ~19). New-onset OCD after age 40 is unusual and should prompt workup for secondary causes.

— Strong heritability (~40–50%); first-degree relatives have 4–5× increased risk.

— Patient describes time-consuming rituals (>1 hour/day), avoidance behaviors, or excessive reassurance-seeking that impair work, school, or relationships.

— Comorbid major depression (up to 60%), generalized anxiety, tic disorders, and substance use.

— Dermatologic clues: chapped/raw hands from washing, trichotillomania-related alopecia, excoriation disorder.

— Pediatric abrupt-onset OCD with tics, choreiform movements, or emotional lability after streptococcal infection → consider PANDAS.

Board pearl: Ego-dystonic intrusive thoughts (the patient is disturbed by them) distinguish OCD from obsessive-compulsive personality disorder (OCPD), where rigid traits are ego-syntonic and consistent with the patient's self-image.

Definition: Obsessive-compulsive disorder (OCD) is a chronic neuropsychiatric condition defined by obsessions (intrusive, unwanted, ego-dystonic thoughts, images, or urges causing marked anxiety) and/or compulsions (repetitive behaviors or mental acts performed to neutralize the obsession or prevent a feared outcome).

Epidemiology:

When to suspect on Step 3:

Common symptom dimensions: contamination/washing, symmetry/ordering, forbidden/taboo thoughts (sexual, religious, aggressive), harm avoidance/checking, and hoarding (now a separate DSM-5 diagnosis but frequently overlapping).

Insight spectrum: DSM-5 specifies good/fair, poor, or absent insight; "absent insight/delusional" OCD can mimic psychosis but the content is fixed on obsessional themes.

Functional burden: WHO ranks OCD among the top 10 causes of disability worldwide; mean delay from symptom onset to diagnosis is 10–17 years.

Presentation Patterns and Key History

— Presence of obsessions, compulsions, or both.

— Time-consuming (>1 hour/day) or cause clinically significant distress/impairment.

— Not attributable to substance, medical condition, or another mental disorder.

— Contamination fears → handwashing, showering, surface cleaning, glove use.

— Doubt ("Did I lock the door? Hit a pedestrian?") → checking, retracing driving routes.

— Symmetry/"just right" feelings → ordering, arranging, counting, tapping.

— Taboo aggressive/sexual/religious thoughts → mental rituals, praying, confessing, reassurance-seeking.

— Fear of harm → avoidance of knives, sharp objects, driving.

— Time spent on obsessions/compulsions per day.

— Degree of resistance and perceived control.

— Interference with occupation, schooling, relationships.

— Insight: "Do you recognize these fears as excessive or unreasonable?"

— Avoidance behaviors and accommodation by family members (family accommodation predicts worse outcome).

— Suicidality: lifetime suicide attempt risk ~10–15%; ask explicitly.

— Substance use, especially alcohol used to suppress anxiety.

— Tic history (comorbidity ~30%, affects medication choice — favor augmentation strategies).

— Trauma history (rule out PTSD intrusions).

— Eating/body image (rule out anorexia, BDD).

Key distinction: Intrusive thoughts in OCD are unwanted and resisted; ruminations in MDD are mood-congruent and not actively neutralized; worries in GAD are about real-life concerns and not paired with compulsions; thought insertion in schizophrenia is attributed to an external source.

Step 3 management: Use the Y-BOCS (Yale–Brown Obsessive Compulsive Scale), the gold-standard severity/treatment-response instrument; ≥16 indicates clinically significant OCD and triggers treatment initiation.

Core diagnostic criteria (DSM-5):

Classic obsession–compulsion pairings to recognize on vignettes:

Targeted history questions (Y-BOCS-informed):

Critical screening additions:

Pediatric considerations: Children may not label thoughts as excessive; ask parents about rituals at bedtime, bathroom, homework, and reassurance-seeking ("Are you sure I'm okay?").

Physical Exam Findings and Behavioral Assessment

— Excoriated, lichenified, fissured hands from compulsive washing or use of harsh cleansers/sanitizers.

— Contact dermatitis from repeated soap exposure.

— Hair loss patches (trichotillomania), skin-picking lesions on extensor surfaces (excoriation disorder) — both OCD-related disorders in DSM-5.

— Dental erosion if compulsive vomiting or excessive brushing.

— Tics (motor: blinking, shoulder shrug; vocal: throat clearing, grunting). Document presence — affects drug choice.

— Choreiform movements in pediatric abrupt-onset cases → PANDAS workup.

— Subtle neurologic asymmetries, basal ganglia signs in late-onset OCD (consider Huntington, Sydenham chorea, lesion).

— Appearance: may be disheveled (avoidance of contamination via showering paradoxically) or excessively groomed.

— Behavior: visible rituals — repeated handwashing in clinic, counting, tapping, lining up items.

— Mood/affect: anxious, often dysphoric; assess for comorbid depression.

— Thought content: obsessional themes; assess insight explicitly.

— Cognition: usually intact; deficits in executive function and set-shifting on formal testing.

— Suicidality: directly assessed and documented.

— Avoidance of handshakes, doorknobs, chairs (contamination concerns).

— Reassurance-seeking from clinician ("Are you sure I won't get sick?"). Avoid reinforcing — therapeutic stance is empathic non-accommodation.

— Family accommodation patterns visible in the room.

Board pearl: Hands with dorsal erythema, fissures, and bleaching in a young adult with no occupational exposure are a classic Step 3 visual clue for contamination-type OCD.

Step 3 management: Document a baseline Y-BOCS score and functional impairment at the index visit to track response — payers and quality measures increasingly require measurement-based care for behavioral health.

General principles: OCD is a clinical diagnosis; physical exam is largely to identify complications of compulsions and to rule out secondary/medical causes.

Dermatologic findings:

Musculoskeletal/neurologic:

Mental status exam (MSE):

Behavioral observation:

Diagnostic Workup — Initial Labs, Imaging, and Secondary Cause Screen

— Ruling out medical mimics.

— Establishing baseline labs before pharmacotherapy.

— Identifying comorbid conditions affecting management.

— CBC, CMP (sodium baseline — SIADH risk, hepatic function).

— TSH (hypo/hyperthyroidism can mimic anxiety/agitation).

— Pregnancy test (β-hCG) in reproductive-age women.

— Consider B12, vitamin D if anxiety/cognitive symptoms.

— Baseline weight, BP, lipids if clomipramine considered.

— ECG if clomipramine, citalopram >20 mg in elderly, or QT-prolonging combinations planned — QTc threshold of concern ≥450 (men)/470 (women); avoid ≥500.

— New-onset OCD after age 40.

— Focal neurologic signs, cognitive decline, atypical movements.

— Abrupt pediatric onset with neurologic findings → strep throat culture/ASO/anti-DNase B titers (PANDAS).

— History of head injury, encephalitis, autoimmune symptoms.

— Consider MRI brain (look for basal ganglia lesions, frontostriatal pathology, demyelination, tumors).

— Autoimmune encephalitis workup (anti-NMDA receptor, anti-basal ganglia antibodies) for atypical adult-onset with rapid progression.

— PHQ-9 for depression, GAD-7 for anxiety, AUDIT-C for alcohol, MDQ for bipolarity (critical — antidepressants can precipitate mania).

— Hoarding-specific scales if symptoms predominate.

— Tic Severity Scale if tics present.

Key distinction: PANDAS/PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) — abrupt OCD/tics in a child within weeks of group A strep (PANDAS) or any infection/immune trigger (PANS), often with separation anxiety, emotional lability, handwriting deterioration; treat the underlying infection and provide standard OCD care.

Board pearl: Always screen for bipolar disorder before starting an SSRI — antidepressant-induced mania is a tested complication, especially in young patients with family history of bipolar illness.

OCD is a clinical diagnosis — no lab or imaging confirms it. Workup is targeted at:

Baseline labs before SSRI initiation:

When to pursue neurologic/medical workup:

Comorbidity screening tools:

Avoid unnecessary testing: Routine MRI, EEG, or extensive autoimmune panels in classic adolescent/young-adult OCD without red flags is low-value care and a frequent Step 3 distractor.

Diagnostic Workup — Advanced and Confirmatory Assessment

— Y-BOCS (clinician-administered, 10 items): severity scoring 0–40 (subclinical <8, mild 8–15, moderate 16–23, severe 24–31, extreme 32–40). Drives treatment intensity and tracks response.

— DOCS (Dimensional Obsessive-Compulsive Scale): symptom-dimension profile.

— Children's Y-BOCS (CY-BOCS) for pediatric patients.

— Rule out OCPD (no true obsessions/compulsions, ego-syntonic perfectionism).

— Rule out body dysmorphic disorder (preoccupation with appearance flaw, mirror-checking).

— Rule out hoarding disorder (now distinct; difficulty discarding, clutter, distress on removal).

— Rule out illness anxiety/somatic symptom disorder (focus is medical illness fears, not contamination ritual).

— Rule out eating disorders, BDD, trichotillomania, excoriation — all in the OCD-related spectrum.

— Functional studies show CSTC circuit (cortico-striato-thalamo-cortical) hyperactivity: orbitofrontal cortex, anterior cingulate cortex, caudate, thalamus.

— Normalization of this circuit correlates with treatment response — useful conceptually for explaining therapy to patients.

— Document family history of OCD, tics, Tourette's, mood/anxiety disorders.

— Genetic testing not routine.

— If tic disorder: assess Tourette criteria (multiple motor + ≥1 vocal tic for >1 year, onset <18).

— If hoarding-predominant: home safety/fire risk assessment, adult protective services if elder at risk.

— Suicide risk assessment (C-SSRS) — especially with comorbid depression.

Step 3 management: Treatment decisions hinge on Y-BOCS severity + insight + comorbidities — mild disease without comorbidity → CBT alone; moderate–severe or with depression → SSRI + CBT combination is preferred.

Board pearl: OCD with poor/absent insight is not psychosis — antipsychotic monotherapy is inappropriate; the first-line remains SSRI ± exposure therapy, with antipsychotic augmentation only after SSRI failure.

Structured diagnostic instruments:

Differential confirmation:

Neuroimaging (research/atypical cases):

Genetic/familial assessment:

Comorbidity-driven workup:

Insight specifier coding (DSM-5): Good/fair, poor, absent/delusional — important because absent-insight OCD has worse SSRI response and may require antipsychotic augmentation earlier.

Risk Stratification and First-Line Management Logic

— Mild (Y-BOCS 8–15), good insight, motivated: Cognitive-behavioral therapy with exposure and response prevention (ERP) as monotherapy — first-line.

— Moderate–severe (Y-BOCS ≥16) or significant comorbid depression: SSRI + ERP combination — superior to either alone.

— Severe (≥24) or absent insight: SSRI at high doses + ERP; consider early psychiatric referral.

— Graded exposure to feared stimulus (touching doorknob) while preventing the compulsive response (no washing).

— Habituation and inhibitory learning reduce anxiety and obsession frequency.

— Typically 13–20 weekly sessions; homework essential.

— Family involvement to reduce accommodation.

— Superior to relaxation, supportive therapy, or generic CBT.

— Higher doses than for depression are typically required.

— Longer trial duration — at least 8–12 weeks at therapeutic dose before declaring failure (vs. 4–6 weeks in depression).

— Response is often partial; goal is ≥35% Y-BOCS reduction or "much/very much improved" on CGI.

— Expect 40–60% response rate; full remission less common.

1. SSRI #1 at adequate dose × 8–12 weeks + ERP.

2. Switch to a different SSRI (or clomipramine) × 8–12 weeks.

3. Augment with low-dose antipsychotic (risperidone, aripiprazole) — especially with tics or poor insight.

4. Consider intensive outpatient ERP, residential, TMS, or in refractory cases deep brain stimulation.

— Set expectation of weeks-to-months for benefit; warn about transient activation/anxiety in first 1–2 weeks.

— Avoid reassurance-giving in clinic — it perpetuates the disorder.

Step 3 management: For a vignette asking "next best step" in newly diagnosed moderate OCD, the highest-yield answer is SSRI + referral for ERP-based CBT, not benzodiazepines and not antipsychotic monotherapy.

Board pearl: Benzodiazepines have no role as primary or maintenance OCD therapy — they may briefly reduce anxiety but worsen avoidance, impair ERP learning, and risk dependence.

Treatment stratification by Y-BOCS severity and impairment:

ERP — the core psychotherapy:

SSRI/SRI principles unique to OCD:

Treatment ladder:

Patient education:

Pharmacotherapy — First-Line Drug Regimens

— Fluoxetine, fluvoxamine, sertraline, paroxetine, clomipramine (TCA, SRI). Escitalopram and citalopram are off-label but evidence-supported.

— Fluoxetine 40–80 mg/day (start 20).

— Sertraline 150–200 mg/day (start 50).

— Fluvoxamine 200–300 mg/day (start 50); strong CYP1A2/2C19 inhibitor — many drug interactions (theophylline, clozapine, tizanidine, warfarin).

— Paroxetine 40–60 mg/day; anticholinergic, sedation, weight gain, withdrawal syndrome on discontinuation, avoid in pregnancy (cardiac malformations).

— Escitalopram 20–40 mg/day (off-label high dose).

— Citalopram capped at 40 mg/day (20 mg if >60 yo or CYP2C19 poor metabolizer) due to QT prolongation.

— Clomipramine 150–250 mg/day — most efficacious in head-to-head trials but limited by anticholinergic effects, sedation, weight gain, seizure risk (>250 mg), and cardiac toxicity. Reserve for SSRI failures.

— Start low (¼ to ½ usual target), uptitrate every 1–2 weeks as tolerated.

— Reach therapeutic dose by week 4; maintain for full 8–12 weeks before declaring nonresponse.

— Document Y-BOCS at baseline, 4, 8, and 12 weeks.

— GI upset, headache, insomnia/somnolence, sexual dysfunction (very common at OCD doses), weight changes.

— Hyponatremia (SIADH) — especially elderly, diuretics.

— Bleeding risk (NSAID, anticoagulant co-use).

— Serotonin syndrome with MAOIs, linezolid, tramadol, triptans (rare), St. John's wort.

— Black-box warning: suicidality in patients <25 — monitor weekly initially.

— Risperidone 0.5–3 mg or aripiprazole 5–15 mg — strongest evidence; especially with tics, poor insight, schizotypal traits.

— Memantine, topiramate, N-acetylcysteine — adjunct evidence weaker.

— Avoid bupropion (not effective) and benzodiazepine maintenance.

Board pearl: Clomipramine has the highest effect size but is second-line because of side-effect burden — Step 3 favors SSRI first, clomipramine after ≥2 SSRI failures, with baseline ECG before initiation.

FDA-approved agents for OCD:

Typical OCD dosing (higher than depression targets):

Titration strategy:

Common adverse effects to counsel:

Augmentation options (post-SSRI failure):

Advanced Pharmacology and Neuromodulation

— Switch to clomipramine (SRI) — efficacy ~60%; obtain baseline ECG (QTc), avoid in significant cardiac disease, monitor levels (target ~150–300 ng/mL parent + desmethyl).

— Augment SSRI with antipsychotic: Risperidone or aripiprazole — strongest evidence; ~⅓ of nonresponders respond to augmentation within 4–6 weeks. Monitor metabolic parameters (weight, BMI, lipids, A1c).

— Combine SSRI + clomipramine (cautiously): synergy but risk of serotonin syndrome and elevated clomipramine levels (fluvoxamine inhibits CYP1A2 → ↑clomipramine); reserve for specialists, monitor ECG and levels.

— Glutamate modulators: memantine 5–20 mg, riluzole, N-acetylcysteine — adjunct evidence in refractory cases.

— Daily or twice-weekly ERP, intensive outpatient programs, partial hospitalization, residential OCD programs for severe/refractory disease.

— Deep TMS (Brainsway H7 coil) — FDA-cleared 2018 for OCD; targets medial prefrontal cortex/ACC; 6-week course, ~30 sessions; option after ≥1 medication trial.

— Repetitive TMS (off-label) — evidence less robust.

— Ablative neurosurgery (anterior cingulotomy, capsulotomy) — historical, rarely used.

— Deep brain stimulation (DBS) — FDA Humanitarian Device Exemption for severe, refractory OCD (≥5 years, ≥2 SSRIs, clomipramine trial, adequate ERP). Targets: anterior limb of internal capsule, nucleus accumbens, STN. Reserved for tertiary centers.

— ECT — not effective for primary OCD; reserved for severe comorbid depression.

— Psilocybin and ketamine — investigational, not standard of care.

— Cannabidiol — insufficient evidence; recreational cannabis often worsens anxiety/OCD.

Step 3 management: After two failed adequate SSRI trials + ERP, the next reasonable steps are switch to clomipramine OR augment with low-dose risperidone/aripiprazole — pick the option matching the vignette's comorbidities (tics → favor antipsychotic; cardiac-clean patient with severe symptoms → clomipramine).

Board pearl: Stimulants and amphetamines are not OCD treatments and can worsen repetitive behaviors and tics; if a vignette adds methylphenidate "to help concentration," that is a wrong answer.

Strategies for SSRI-resistant OCD (treatment-resistant = ≥2 adequate SSRI trials + adequate ERP):

Intensive psychotherapy:

Neuromodulation:

Emerging therapies:

Special Populations — Elderly and Renal/Hepatic Impairment

— New-onset OCD after 50 is unusual — investigate secondary causes: stroke (basal ganglia), neurodegenerative disease (frontotemporal dementia, Parkinson's, Huntington's), CNS tumor, autoimmune.

— Obtain MRI brain, cognitive screening (MoCA), and targeted neurologic exam.

— Citalopram capped at 20 mg/day in patients >60 — QT prolongation risk; obtain baseline and follow-up ECG if titrating.

— Escitalopram preferred over citalopram (cleaner QT profile, still cap at 10–20 mg in elderly).

— Sertraline often first choice — fewer drug interactions, manageable side effects.

— Avoid paroxetine — high anticholinergic burden (Beers criteria), falls, cognitive impairment.

— Avoid clomipramine when possible — anticholinergic delirium, orthostasis, cardiac conduction effects, urinary retention.

— Watch for SIADH/hyponatremia — check Na within 2–4 weeks of SSRI start, especially with thiazides, low body weight, or concurrent anticonvulsants.

— Bleeding risk with NSAIDs, antiplatelets, anticoagulants — consider PPI cover or alternative.

— Fall risk: dizziness, orthostasis, sleep effects.

— Most SSRIs are hepatically metabolized; dose adjustment usually not needed for renal disease, but start low and titrate slowly.

— Paroxetine: reduce dose in severe renal impairment.

— Avoid lithium augmentation in CKD.

— Reduce SSRI dose by 50% in moderate–severe hepatic dysfunction; preferred agents include escitalopram or sertraline at conservative dosing.

— Avoid fluvoxamine and clomipramine — extensive hepatic metabolism and drug interactions.

— Fluoxetine, paroxetine = strong CYP2D6 inhibitors (interact with metoprolol, tamoxifen, opioids).

— Fluvoxamine = strong CYP1A2/2C19 inhibitor (warfarin, theophylline, clozapine, tizanidine).

— Citalopram + ondansetron, methadone, antipsychotics → additive QT risk.

Step 3 management: In a frail elder with late-onset OCD, MRI brain + cognitive testing precede initiation of pharmacotherapy, and sertraline at low dose with sodium monitoring is the typical first-line drug.

Key distinction: OCD-like behaviors in frontotemporal dementia (bvFTD) are accompanied by disinhibition, apathy, and executive decline — treat the dementia; SSRIs may help behaviorally but do not address core pathology.

Geriatric OCD:

Pharmacologic considerations in elderly:

Renal impairment:

Hepatic impairment:

Polypharmacy alert:

Special Populations — Pregnancy, Pediatrics, and Perinatal OCD

— Pregnancy and postpartum periods are high-risk windows — new onset or exacerbation in up to 30% of women with prior OCD.

— Common theme: intrusive thoughts of harming the infant (drowning, dropping) — ego-dystonic, the mother is horrified.

— Crucial differential: postpartum psychosis (ego-syntonic delusions, disorganization, command hallucinations) — psychiatric emergency, hospitalize, do not leave alone with infant.

— CBT/ERP is first-line — no fetal exposure.

— If medication needed for moderate–severe disease: sertraline preferred (lowest placental transfer, extensive safety data, compatible with breastfeeding).

— Avoid paroxetine (associated with cardiac defects — FDA category D historically).

— Discuss small absolute risks: persistent pulmonary hypertension of the newborn (PPHN, ~2–3/1000 vs 1–2/1000 baseline), neonatal adaptation syndrome (transient jitteriness, feeding difficulty — usually resolves in days).

— Do not abruptly stop SSRI at delivery — relapse risk is high; weigh against neonatal symptoms.

— Postpartum: support breastfeeding on sertraline; monitor infant.

— Onset typically 7–12 years; CY-BOCS for severity.

— First-line: CBT with ERP for mild–moderate OCD.

— Moderate–severe or partial CBT response: add SSRI — sertraline, fluoxetine, fluvoxamine FDA-approved in pediatrics; start at ½ adult starting dose, titrate to effect.

— Black-box warning: increased suicidal ideation in patients <25 — weekly monitoring × 4 weeks, then biweekly × 4 weeks per FDA.

— Family-based CBT improves outcomes; address parental accommodation.

— Screen for tics, ADHD, autism spectrum, learning disabilities.

— Abrupt onset OCD/tics with prodromal infection in a child.

— Treat underlying strep with antibiotics (penicillin/amoxicillin).

— Standard OCD treatment (CBT ± SSRI) for symptoms.

— IVIG and plasmapheresis controversial — specialist territory.

Board pearl: Postpartum mother with intrusive thoughts of harming her baby that she finds horrifying and resists = postpartum OCD (outpatient SSRI + CBT, safe with infant); commanded by voices or believes the baby is evil = postpartum psychosis (emergent hospitalization, never leave with infant).

Perinatal OCD:

Treatment in pregnancy:

Pediatric OCD:

PANDAS/PANS:

Complications and Adverse Outcomes

— Major depressive disorder (lifetime ~60%) — leading cause of suicidality in OCD.

— Suicide attempts in ~10–15% lifetime; ideation in up to 50%. Higher risk with comorbid depression, hopelessness, severe symptoms, substance use.

— Substance use disorders (alcohol most common) as self-medication.

— Comorbid anxiety disorders, eating disorders, BDD, hoarding, tics/Tourette's.

— Social isolation, occupational disability, school dropout.

— Dermatologic: contact dermatitis, cellulitis from broken skin (washing); trichotillomania-related alopecia and trichobezoars; skin-picking infections.

— Dental: erosion from compulsive brushing or vomiting.

— Musculoskeletal: repetitive strain from rituals (counting, tapping).

— Nutritional: restrictive eating from contamination fears → weight loss, vitamin deficiency.

— Hoarding: fire hazards, falls, vermin, social services involvement.

— Serotonin syndrome (SSRI + MAOI, linezolid, tramadol, triptans, MDMA, St. John's wort): triad of mental status change, autonomic instability, neuromuscular hyperactivity (clonus, hyperreflexia).

— Hyponatremia/SIADH — confusion, falls, seizures in severe cases.

— Bleeding (GI, intracranial) — additive with NSAIDs, anticoagulants.

— Sexual dysfunction (very common, often dose-related; consider dose reduction, bupropion augmentation, or switch).

— QTc prolongation (citalopram, escitalopram at high dose; clomipramine).

— Weight gain, metabolic effects (paroxetine, antipsychotic augmentation).

— Discontinuation syndrome (paroxetine > sertraline > fluoxetine): flu-like symptoms, dizziness, "brain zaps," irritability — taper slowly.

— Antidepressant-induced mania in undiagnosed bipolar disorder.

— Brief symptom intensification during ERP exposures (expected, not a failure).

— Family conflict when accommodation is withdrawn — provide family psychoeducation.

Step 3 management: A patient on fluoxetine + tramadol presenting with confusion, hyperthermia, clonus, diaphoresis has serotonin syndrome — discontinue serotonergic agents, supportive care, benzodiazepines, consider cyproheptadine for moderate–severe cases.

Board pearl: Sudden cessation of paroxetine classically produces discontinuation syndrome within 24–72 hours; switch to fluoxetine taper or reduce by 10% every 2 weeks.

Functional and psychiatric complications:

Medical complications of compulsions:

Pharmacotherapy-related complications:

Therapy-related risks:

When to Escalate Care — Referral and Inpatient Triage

— Active suicidal ideation with plan/intent or recent attempt.

— Inability to perform basic self-care or eat due to severity.

— Psychotic features (true psychosis vs. absent-insight OCD must be distinguished).

— Severe comorbid depression with neurovegetative collapse.

— Concern for postpartum psychosis (vs. postpartum OCD) — admit emergently.

— Threats of harm to others, including children, even when ego-dystonic — assess capability and protective factors carefully; document and create safety plan.

— Y-BOCS ≥24 (severe).

— Failure of first SSRI trial.

— Diagnostic uncertainty (rule out psychotic, bipolar, autism spectrum).

— Children with severe OCD or PANDAS workup.

— Pregnancy/postpartum requiring perinatal psychiatry input.

— Treatment-resistant OCD for clomipramine, augmentation, TMS, or DBS evaluation.

— OCD specialist/CBT-ERP therapist — every moderate–severe case; primary care often the bottleneck for ERP access.

— Neurology — atypical onset, focal findings, suspected secondary OCD.

— Genetics — Huntington's family history with new-onset OCD/tics.

— Social work — hoarding with safety risk, family accommodation severe, school issues.

— Intensive Outpatient Program (IOP, 3 hrs × 3 days/week).

— Partial Hospitalization Program (PHP, 6 hrs × 5 days/week).

— Residential OCD programs (2–12 weeks) for severe refractory disease.

— Order: PHQ-9, GAD-7, Y-BOCS, C-SSRS, TSH, CBC, CMP, β-hCG, AUDIT-C.

— Start: sertraline 50 mg daily, titrate weekly to 200 mg.

— Refer: CBT with ERP, weekly.

— Follow-up: 2 weeks (tolerance, suicide check), 4 weeks (titration), 8 weeks (response), 12 weeks (formal response assessment).

— Reassess: if <35% Y-BOCS reduction at 12 weeks at adequate dose → switch or augment.

CCS pearl: Document a safety plan (warning signs, coping strategies, social contacts, professional contacts including 988, means restriction) in every OCD patient with depressive symptoms — this is both clinically essential and a tested patient-safety element.

Immediate psychiatric emergency (ED/inpatient admission):

Urgent outpatient psychiatry referral (within 1–2 weeks):

Subspecialty referrals:

Intensive levels of care:

CCS-style management cascade for moderate–severe OCD vignette:

Key Differentials — Other Anxiety and OCD-Spectrum Disorders

— Body dysmorphic disorder (BDD): preoccupation with perceived appearance flaw not observable to others; mirror-checking, grooming, reassurance-seeking, skin-picking. Treat with SSRI + CBT; do not pursue cosmetic surgery — does not improve symptoms and may worsen them.

— Hoarding disorder: persistent difficulty discarding possessions; clutter precludes use of living spaces. CBT specialized for hoarding > SSRI; medication evidence weaker.

— Trichotillomania: recurrent hair pulling with hair loss. First-line habit reversal training; N-acetylcysteine, SSRIs adjunct.

— Excoriation (skin-picking) disorder: recurrent skin picking with lesions. Same approach as trichotillomania.

— GAD: excessive worry about multiple real-life domains, no rituals; worries are ego-syntonic and reality-based. SSRI/SNRI + CBT.

— Panic disorder: discrete panic attacks ± agoraphobic avoidance; not theme-driven obsessions. SSRI + CBT.

— Social anxiety: fear of scrutiny; situational, no rituals.

— Specific phobia: fear of specific stimulus, avoidance without complex ritual.

— Illness anxiety disorder: preoccupation with having serious illness despite reassurance; closer to OCD spectrum but lacks compulsive rituals.

Key distinction: Both GAD and OCD involve excessive cognitions, but GAD worries are about realistic future concerns (finances, health, family) and lack compulsions to neutralize them; OCD obsessions are intrusive, often bizarre or taboo, and paired with specific rituals.

Board pearl: A patient seeking repeated rhinoplasty for a nose she perceives as "deformed" despite normal appearance has BDD — refuse cosmetic intervention, refer for SSRI + CBT.

OCD-related disorders (DSM-5 chapter):

Anxiety spectrum:

PTSD: intrusive memories tied to traumatic event; flashbacks, hyperarousal, avoidance. Content is trauma-related, not obsessional.

Tic disorders/Tourette's: premonitory urge → motor/vocal tic; tic feels "needed," but less cognitively elaborated than OCD obsession. Co-occurs in 30% of OCD. Treat with habit reversal, α2-agonists (clonidine, guanfacine), antipsychotics if severe.

Eating disorders: ritualized food behaviors but content is body/weight-focused.

Key Differentials — Non-Anxiety Mimics

— Pervasive pattern of perfectionism, rigidity, control, preoccupation with order/rules, workaholism, miserliness.

— Ego-syntonic — patient sees traits as virtues, not distressing intrusions.

— No true obsessions or compulsions; coworkers/family suffer more than the patient.

— Treat with psychotherapy (psychodynamic, CBT); medications limited utility.

— Schizophrenia: thought insertion/broadcasting, hallucinations, disorganization, negative symptoms.

— Delusional disorder: fixed false belief, often non-bizarre, without other psychotic features.

— Differentiate from absent-insight OCD — OCD content is obsessional (contamination, harm, symmetry); patient may briefly entertain doubt under questioning and lacks broader psychotic features.

— Restricted, repetitive behaviors (stereotypies, insistence on sameness) without anxiety-driven obsessions.

— Behaviors often pleasurable or self-soothing rather than ego-dystonic.

— High OCD comorbidity in ASD complicates assessment.

— Sydenham chorea, PANDAS (post-strep, pediatric).

— Huntington's disease: OCD features + chorea + cognitive decline + family history (AD).

— Parkinson's disease / DLB: repetitive behaviors (punding) especially on dopamine agonists.

— Frontotemporal dementia (bvFTD): compulsive eating, hoarding, ritualistic behaviors with disinhibition.

— Stroke of basal ganglia/caudate: acquired OCD.

— TBI, anoxic injury, encephalitis — secondary OCD.

— Autoimmune encephalitis (anti-NMDA, anti-basal ganglia).

— Stimulants, cocaine → repetitive stereotyped behaviors (punding).

— Withdrawal states can amplify anxiety/obsession features.

Key distinction: OCD vs. OCPD is the single most frequently tested differential — OCD = unwanted intrusive thoughts the patient resists (ego-dystonic, often presents asking for help); OCPD = rigid personality traits the patient defends (ego-syntonic, often presents at the urging of family or boss).

Board pearl: New-onset OCD in a 45-year-old with subtle chorea and a parent with "psychiatric problems and movement disorder" → Huntington's disease — order genetic counseling and HTT trinucleotide testing.

Obsessive-compulsive personality disorder (OCPD):

Psychotic disorders:

Autism spectrum disorder (ASD):

Neurologic/medical mimics:

Substance-induced:

Maintenance Treatment, Discharge Medications, and Long-Term Plan

— Continue effective SSRI at full therapeutic dose for at least 1–2 years after response.

— For multiple episodes or severe baseline disease, consider indefinite maintenance — OCD is typically chronic and relapsing.

— Relapse rate after SSRI discontinuation is >50% within 1 year.

— Decrease by 10–25% every 1–2 months while monitoring Y-BOCS.

— Maintain ERP skills/booster sessions during taper.

— Resume previous effective dose if symptoms return.

— Avoid abrupt discontinuation (paroxetine, fluvoxamine highest withdrawal risk; fluoxetine self-tapers due to long half-life).

— Continued exposure exercises maintained as a "lifestyle."

— Booster CBT sessions every 3–6 months during medication taper.

— Combined CBT + SSRI yields lower relapse on discontinuation than SSRI alone.

— Medication reconciliation with explicit dose, taper plan, refill quantity.

— Outpatient psychiatry follow-up within 1–2 weeks.

— Outpatient therapist (CBT/ERP) scheduled within 1 week.

— Safety plan documented; lethal means counseling.

— PCP notified; warm hand-off communication.

— Family psychoeducation completed.

— 988 crisis line, local crisis numbers given.

— Sleep hygiene (sleep deprivation worsens symptoms).

— Aerobic exercise (modest evidence as augmentation).

— Limit caffeine, alcohol, cannabis, stimulants — all can worsen OCD.

— Mindfulness as adjunct, not substitute for ERP.

— Continue depression treatment in parallel.

— Address tics, ADHD, eating disorders concurrently — siloed treatment fails.

Step 3 management: A patient in remission for 1 year on sertraline 200 mg requesting discontinuation should be counseled that continued treatment reduces relapse, and if tapering is pursued, it should be slow, gradual, accompanied by ongoing CBT-ERP, and monitored with serial Y-BOCS.

Board pearl: Combined CBT + SSRI has the lowest long-term relapse rate — therapy is not just "an option" but a relapse-prevention intervention.

Duration of pharmacotherapy:

Tapering principles:

CBT/ERP long-term role:

Discharge checklist after inpatient or IOP stay:

Lifestyle and complementary measures:

Comorbidity maintenance:

Follow-Up, Monitoring Parameters, and Rehabilitation

— Week 1–2: tolerability, side effects, suicide check (especially <25 yo), adherence.

— Week 4: dose titration, partial response assessment.

— Week 8: therapeutic-dose effect assessment.

— Week 12: formal response evaluation (Y-BOCS), decide continue/switch/augment.

— Stable maintenance: every 3 months, then every 6 months once stable for a year.

— During taper: monthly Y-BOCS + clinical check.

— All SSRIs: weight, BP, suicidality, sexual function, GI tolerance, bleeding risk.

— Citalopram/escitalopram at high dose: ECG (QTc) at baseline and after each dose increase, especially elderly or polypharmacy.

— Clomipramine: baseline and follow-up ECG, drug levels, anticholinergic check, weight, glucose.

— Antipsychotic augmentation: weight/BMI, waist, BP, fasting glucose/HbA1c, lipids at baseline, 12 weeks, then annually; AIMS for tardive dyskinesia at baseline and every 6–12 months.

— Sodium at 2–4 weeks in elderly on SSRI.

— Repeat Y-BOCS at each visit during titration; documentation supports value-based care metrics.

— PHQ-9, GAD-7, C-SSRS at each visit.

— Vocational rehab if work-disabled.

— School accommodations (IEP/504 plan) for pediatric OCD — extended time, breaks, reduced homework, in-school CBT support.

— Peer support groups (IOCDF — International OCD Foundation).

— Family therapy to dismantle accommodation patterns.

— Pediatric → adult psychiatry handoff at 17–18: medication continuity, therapist transition, college mental health resources.

— Postpartum continuation of meds with clear lactation counseling.

Step 3 management: Track response with serial Y-BOCS scores at 0, 4, 8, and 12 weeks; a <25% reduction at adequate dose × 12 weeks defines nonresponse and triggers the next algorithm step (switch or augment).

CCS pearl: Order fasting lipids, glucose, and weight before starting antipsychotic augmentation, then at 12 weeks, then annually — metabolic monitoring is a tested patient-safety standard.

Follow-up cadence in primary care/psychiatry:

Monitoring parameters by drug:

Measurement-based care:

Rehabilitation and psychosocial support:

Transitions of care:

Ethical, Legal, and Patient Safety Considerations

— Discuss black-box warning of increased suicidality in patients <25 with all antidepressants; document conversation.

— Discuss sexual dysfunction (often deal-breaker; under-disclosed historically).

— In pregnancy, document shared decision-making weighing untreated OCD risks (poor self-care, suicide, postpartum decompensation) against medication risks; refusing to medicate severe perinatal OCD is itself a patient-safety concern.

— Parental consent + adolescent assent for treatment.

— Confidentiality balanced with safety: disclose to parents for imminent risk; otherwise respect adolescent's confidentiality within state law.

— Intrusive thoughts of harming a child in postpartum OCD are typically ego-dystonic and not predictive of action — careful risk assessment, do not reflexively involve CPS.

— However, if behavioral evidence suggests risk (e.g., command hallucinations, psychotic features, neglect), child protective services must be notified per state law.

— Tarasoff duty: if a patient expresses credible intent to harm an identifiable victim, warn and/or protect; rare in OCD but possible.

— Severe OCD rarely impairs decision-making capacity unless psychotic-level absent insight + comorbid psychosis.

— Involuntary hospitalization criteria (danger to self, danger to others, grave disability) — apply standard state thresholds.

— Discharge from inpatient unit without follow-up within 7–14 days is a major suicide-risk window — schedule before discharge, confirm patient has the appointment.

— Medication reconciliation errors at handoffs (paroxetine taper, clomipramine dose) — explicit instructions.

— Pediatric → adult care transition: 18-year-olds frequently lose insurance coverage, therapist continuity, parental medication oversight.

— ERP-trained therapists are scarce — referral may take months; telehealth and digital ERP platforms (FDA-cleared) help close the gap.

— Insurance parity (MHPAEA) — escalate denials of medically necessary IOP/residential care.

— Safety plan, capacity assessment, informed consent, family communication, follow-up plan.

Step 3 management: A postpartum patient describing intrusive thoughts of drowning her infant that terrify her, that she actively avoids being alone with the baby to prevent acting on, requires urgent psychiatric evaluation, ERP-focused treatment, sertraline initiation, and a safety/support plan, NOT reflexive CPS referral — distinguishing OCD from postpartum psychosis is the central clinical and ethical decision.

Informed consent for OCD pharmacotherapy:

Pediatric and adolescent consent:

Mandatory reporting and duty to protect:

Capacity and refusal of care:

Transition-of-care risks:

Equity and access:

Documentation imperatives:

High-Yield Associations and Rapid-Fire Clinical Facts

• Neurobiology: dysfunction of the cortico-striato-thalamo-cortical (CSTC) loop — orbitofrontal cortex, anterior cingulate, caudate, thalamus hyperactivity; serotonin and glutamate dysregulation; treatment normalizes circuit activity.
• Genetics: ~40–50% heritability; first-degree relatives 4–5× risk; SLC1A1 (glutamate transporter), serotonin transporter polymorphisms implicated.
• Comorbidity rates: MDD ~60%, anxiety disorders ~75%, tic disorders ~30%, ADHD ~15%, eating disorders ~10%, BDD ~10%, hoarding ~10%.
• Y-BOCS bands: subclinical <8	mild 8–15	moderate 16–23	severe 24–31	extreme 32–40. ≥16 = treat.
• First-line drugs: SSRI (sertraline, fluoxetine, fluvoxamine, paroxetine, escitalopram, citalopram with caps) at high doses for 8–12 weeks.
• Most effective single drug: clomipramine — but second-line due to anticholinergic and cardiac effects.
• First-line psychotherapy: Exposure and Response Prevention (ERP) — more effective than relaxation or generic CBT.
• Augmentation of choice for SSRI partial response: low-dose risperidone or aripiprazole, especially with tics or poor insight.
• Pregnancy: sertraline preferred; paroxetine avoided (cardiac malformations).
• Pediatric FDA-approved SSRIs for OCD: sertraline (≥6 yo), fluoxetine (≥7), fluvoxamine (≥8); clomipramine (≥10).
• Citalopram cap: 40 mg adults / 20 mg elderly or CYP2C19 poor metabolizer (QT).
• Drugs to AVOID/limit: benzodiazepines (no monotherapy role), stimulants (worsen tics), bupropion (ineffective for OCD).
• PANDAS: sudden pediatric OCD/tics post-strep; treat infection + standard OCD care.
• Postpartum OCD vs. postpartum psychosis: ego-dystonic vs. ego-syntonic — different treatment, different urgency.
• Hoarding: separate DSM-5 disorder; CBT specialized; weak SSRI evidence.
• Trichotillomania/excoriation: habit reversal training first; N-acetylcysteine adjunct.
• OCPD: ego-syntonic perfectionism, no true compulsions; treat with psychotherapy.
• Refractory OCD options: clomipramine, antipsychotic augmentation, deep TMS, residential ERP, DBS.
• Suicide risk: ~10–15% lifetime attempt; screen at every visit.
• Relapse risk off medication: >50% in 1 year; combination CBT + SSRI lowers relapse.
Board pearl: "Higher dose, longer trial" — OCD requires SSRI doses above depression targets and ≥8–12 weeks before declaring failure; vignettes that change drugs at 4 weeks at low dose are wrong-answer traps.

Board Question Stem Patterns

Step 3 management: Most OCD wrong answers on Step 3 involve premature medication switching, benzodiazepine monotherapy, antipsychotic monotherapy, or paroxetine in pregnancy — recognize these patterns instantly.

Stem 1 — Classic adolescent OCD: 16-year-old washes hands until raw, late to school, knows it's unreasonable. Best initial therapy? → CBT with exposure and response prevention (mild–moderate, motivated, with insight = ERP monotherapy first; SSRI + ERP also acceptable if moderate severity).

Stem 2 — Adult with moderate–severe OCD: Y-BOCS 22, contamination obsessions, comorbid depression. Next step? → Sertraline + referral for ERP.

Stem 3 — Inadequate response: Fluoxetine 40 mg × 12 weeks, partial response. Next step? → Increase fluoxetine to 80 mg (use full dose range before declaring failure) OR switch to another SSRI; not yet clomipramine or antipsychotic.

Stem 4 — Treatment resistance: Failed sertraline and fluoxetine at full dose × 12 weeks each with ERP. Next? → Clomipramine OR augment with risperidone/aripiprazole.

Stem 5 — Tics present: OCD with motor and vocal tics, partial SSRI response. → Augment SSRI with aripiprazole or risperidone.

Stem 6 — Pregnancy: First-trimester woman with worsening OCD. → CBT/ERP first; if medication needed, sertraline; avoid paroxetine.

Stem 7 — Postpartum intrusive thoughts of harm to baby, ego-dystonic, distressed: → Postpartum OCD — outpatient sertraline + CBT, supportive plan. NOT postpartum psychosis, NOT CPS reflexively.

Stem 8 — Postpartum delusional belief baby is possessed, command voices: → Postpartum psychosis — emergency hospitalization, never alone with infant, antipsychotic + mood stabilizer ± ECT.

Stem 9 — Elder with new-onset OCD age 60, gait abnormalities, dementia screen abnormal: → MRI brain + neurology referral, evaluate for secondary cause; do not just start SSRI.

Stem 10 — Pediatric abrupt OCD with strep history: → PANDAS — strep cultures/ASO, antibiotics, standard OCD treatment.

Stem 11 — OCPD differential: Workaholic accountant who insists colleagues follow his rigid filing system, ego-syntonic, no rituals → OCPD, psychotherapy.

Stem 12 — Side effect on SSRI: Elderly woman on sertraline + HCTZ with confusion and Na 124 → SSRI-induced SIADH, discontinue/replace SSRI, treat hyponatremia carefully.

Stem 13 — Serotonin syndrome: Patient on fluoxetine started on tramadol with hyperthermia, clonus, agitation → discontinue serotonergic agents, supportive care, benzodiazepines, cyproheptadine if moderate–severe.

Stem 14 — Discontinuation syndrome: Stopped paroxetine abruptly, now flu-like, "brain zaps" → resume paroxetine and taper slowly (or bridge with fluoxetine).

Stem 15 — BDD masquerading: Patient seeking 4th rhinoplasty for "deformed" normal nose → BDD, refer for SSRI + CBT, decline surgery.

One-Line Recap

OCD is a chronic CSTC-circuit disorder of ego-dystonic obsessions and compulsions, diagnosed clinically with the Y-BOCS, treated first-line with exposure-and-response-prevention CBT and high-dose, long-trial SSRIs (sertraline, fluoxetine, fluvoxamine, paroxetine, escitalopram), and escalated by switching SSRIs, adding clomipramine, or augmenting with low-dose risperidone/aripiprazole before considering deep TMS or DBS.

Board pearl: When in doubt on a Step 3 OCD question, the answer is almost always "SSRI at OCD-level dose for 8–12 weeks plus exposure-and-response-prevention therapy" — and the wrong answer is almost always a benzodiazepine, antipsychotic monotherapy, paroxetine in pregnancy, or premature medication switching.

Diagnose: Ego-dystonic obsessions + compulsions, >1 hr/day or impairment; confirm with Y-BOCS; screen for depression, suicidality, bipolar, tics, substance use; differentiate from OCPD (ego-syntonic), psychosis (true delusions/hallucinations), and PANDAS (pediatric, post-strep, abrupt).

Treat: Mild → ERP alone; moderate–severe → SSRI + ERP at higher doses, longer (8–12 week) trials than depression; clomipramine reserved for SSRI failures; antipsychotic augmentation for partial response, tics, or absent insight; benzodiazepines and stimulants have no role.

Special populations: Sertraline in pregnancy, avoid paroxetine; sertraline/fluoxetine/fluvoxamine FDA-approved in pediatrics with black-box suicidality monitoring; cap citalopram in elderly for QT; investigate new-onset OCD after 40 with neurologic workup.

Maintain: Continue effective treatment 1–2 years minimum after response (often indefinite); combine CBT + SSRI for lowest relapse; safety plan and measurement-based care (serial Y-BOCS, PHQ-9, C-SSRS) at every visit; coordinate transitions of care to prevent post-discharge relapse and suicide risk.